Company ProfilePremium

Nanollose Limited

Company Profile Analysis

Ticker: NC6.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Nanollose Limited - Company showcase

Year Founded & Workforce

2014

971,000 Employees

Nanollose Limited logo

Nanollose Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Nanollose Limited Overview

Nanollose is a pre-revenue Western Australian advanced-biomaterials company. It is commercialising microbial (bacterial) cellulose as a non-forestry feedstock for the US$20bn-plus man-made cellulosic fibre (MMCF) industry. Its process ferments food and agricultural waste streams into cellulose that is more than 99% pure, in days rather than decades. That cellulose is processed into a pulp that can be fed directly into existing lyocell lines alongside wood pulp, producing its flagship Nullarbor™ "Forest-Friendly" fibre. After a FY2026 strategic review under new CEO Andrew Moullin, the company narrowed its focus from a multi-product platform (textile fibre, nonwoven fibre, horticultural gel, leather alternative) to Nullarbor alone. It now intends to build and control a single Pilot Facility in Western Australia, generate industrial-grade process data, and monetise the process through licensing, joint venture or sale to incumbent fibre producers rather than building its own industrial capacity. The company has a market capitalisation of about A$20m, A$1.33m of cash (30 June 2026), and a going-concern material uncertainty.


Company's own description (FY2026 Annual Report, paraphrased). The company calls itself an advanced biomaterials company working to commercialise technology that creates fibres, fabrics and other materials from microbial cellulose. In FY2026 its principal activities were research and development and the work needed to scale its microbial cellulose technologies. After a portfolio review completed during the year, the company narrowed its primary near-term focus to the development, scale-up and commercialisation of Nullarbor™, its Forest-Friendly MMCF for textiles.

How the technology works. Wood contains less than 50% cellulose, so dissolving pulp requires large-scale logging and chemical pulping. Nanollose instead uses a fermentation process, which the company likens to brewing kombucha. Bacteria convert food waste, agricultural waste and by-products (sugar, wine, beer and coconut-water streams have been referenced historically) into microbial cellulose (MC) that is more than 99% pure. The MC is grown in trays over about 10–15 days by contract partner Hainan Guangyu Biotechnology (HGB) in Haikou, China. It is then purified, dewatered and processed into a pulp. In the lyocell route, that pulp is co-dissolved with FSC-certified wood pulp in N-methylmorpholine N-oxide (NMMO) solvent and spun on standard lyocell equipment at partner Birla Cellulose in India. The resulting fibres are named by MC content (Nullarbor-20, -25 and -30 contain 20%, 25% and 30% MC respectively).

Business model. The intended model is technology monetisation, not manufacturing at scale. Management's FY2026 letter says the asset is "the process, not the Pilot Plant." The company plans to prove the process at a scale the industry recognises, then deploy it inside existing third-party plants through:

  • licence (royalty on third-party tonnes);

  • joint venture; or

  • outright sale of the technology and know-how.

Revenue model mix. There is currently no operating revenue.

Value-chain position. Nanollose sits upstream as a feedstock and process-technology provider.

Customer types and end-markets. The target customers are MMCF producers (lyocell, viscose and modal makers), who would buy pulp or license the process. The secondary "pull" audience is fashion and textile brands with deforestation-free or traceability commitments. Historic or deprioritised end-markets are hygiene and wet-wipe nonwovens (Nufolium), vertical-farming and microgreens horticulture (Biollose MicroGel / Jelli Grow), and leather-alternative materials.

Independent characterisation. Nanollose is best understood as an early-stage, single-asset, pre-commercial process-technology company. Its value rests on three things:

  1. whether a laboratory-scale process improvement (at least 80% efficiency gain, one production stage removed, announced April 2026) holds at pilot scale;

  2. whether a self-built Western Australian Pilot Facility can be funded from a A$1.3m cash base and a roughly A$20m market capitalisation without severe dilution; and

  3. whether a major MMCF producer, most plausibly existing partner Birla Cellulose, will sign a commercial licence.

The "drop-in feedstock" positioning is a genuine strategic merit. Nanollose does not ask the industry to scrap existing lyocell assets, unlike some next-generation fibre rivals that require new spinning technology. The company has now completed four pilot spins over four years (2022–2026) without a binding offtake.

Strategy

Stated strategy themes (FY2026 Annual Report and the 8 April 2026 CEO letter, paraphrased)

  1. Single flagship focus. Concentrate scarce capital and technical resources on Nullarbor™ fibre. Biollose, leather-like materials and Nufolium remain in the IP portfolio but are off the near-term agenda.

  2. Complement the incumbents, don't compete with them. Nullarbor is designed as an incremental, fungible feedstock for existing lyocell lines, which lowers adoption barriers. The company does not intend to build industrial MMCF capacity.

  3. Monetise the process. Value creation is through licence, joint venture or sale to major producers. Management highlights that licence income scales on other parties' capital and customers.

  4. Build and control a single Western Australian Pilot Facility. This replaces the earlier two-stage (pilot plus demonstration line), capital-light, partner-backed model described in the March 2026 quarter. The rationale is speed of iteration, control over pace, protection of know-how, and lower total pre-revenue operating cost.

  5. Onshore capability. Analytical, testing and process-development work moves to Australia, which may also unlock Australian non-dilutive R&D grants (an advisor has been engaged).

  6. Staged procurement. Capex is to be committed progressively as each stage is specified. The overall funding approach is not yet determined.

  7. Tailwinds from regulation and brand commitments. The EU Deforestation Regulation (EUDR) and brand commitments to traceability and non-forest feedstocks are cited as demand drivers.

Initiative register (last 24 months)

InitiativeDateDescriptionStatus
Strategic capital raise (placement, rights issue, director fee conversion)Dec 2024 – May 2025About A$2.1m (A$672k placement, A$1.05m rights issue, A$400k fee-to-equity) with attaching optionsCompleted
Paradise Textiles JV (non-binding)Jul 2024Joint development and commercialisation of Nullarbor yarns and fabricsOngoing; fourth-spin fibre with Paradise for conversion
Waverley Mills blanket projectApr 2025First finished consumer product (about 70 blankets)Completed; exhibited at NGV
Nufolium/Magnera/Codi wipes trial2024 – Jul 2025110kg fibre converted into nonwoven rolls and wipesCompleted; programme deprioritised
CEO appointment and executive restructuringJul 2025Moullin as CEO/MD; Best refocused on technology and R&DCompleted
Fiftyone Capital option commitment and advisory mandateAug 2025A$750k in three tranches; corporate advisory (12 months)Completed (tranches received Sep 2025 – Mar 2026)
Portfolio strategic reviewFY2026 H1Narrowed focus to NullarborCompleted
Fourth pilot spinFeb 2026580kg of fibre; first spin with no Birla pre-processingCompleted
Process-efficiency programmeMar – Apr 2026At least 80% efficiency gain; one stage removed (laboratory scale)Completed at lab scale; pilot validation pending
Pilot Facility (Western Australia)Apr 2026 – ongoingGlobal equipment tender; site selection; staged procurementIn progress; cost not disclosed
Onshoring of analytics and testingJun-2026 quarter – ongoingLaboratory equipment delivered to Western AustraliaIn progress
Engineering team build-outJun – Aug 2026Nardini (Ops & Engineering), Hillier and Brown (consultants)Completed hires; further consultants in discussion
Non-dilutive grant pursuitFY2026 – FY2027Australian R&D grants tied to onshore activityIn progress
Cost disciplineMar – May 2026Chairman salary cut of about 58%; non-executive fee cut of about 42%Implemented

ESG/sustainability commitments

These are product-intrinsic and not formal targets. The company positions Nullarbor as reducing reliance on logging, citing Canopy's estimate that more than 300 million trees are logged a year for fashion. No corporate emissions targets have been published.

Management targets and guidance

FY2027 operating "markers" (CEO letter, FY2026 Annual Report):

  1. Secure and fit out Western Australian premises.

  2. Complete the equipment tender and costing, and disclose the facility's cost and output.

  3. Install and commission onshore equipment.

  4. Complete larger-volume dewatering and washing trials and finalise specifications.

  5. Build, commission and run the Pilot Facility.

  6. Use its output to convert partner evaluations into formal commercial agreements.

There is no financial guidance (revenue, EBITDA or capex) and no medium-term financial targets.

Products & Services

The single reporting segment is organised here by technology programme.

Nullarbor™ Forest-Friendly lyocell/rayon fibre (flagship)

AttributeDetail
DescriptionMan-made cellulosic fibre produced by co-dissolving Nanollose microbial-cellulose pulp with FSC-certified wood pulp in a conventional lyocell process. It is positioned as an "incremental, fungible feedstock" for existing lyocell lines
VariantsNullarbor-20 (20% MC; 250kg first pilot spin, 2022; 50kg used for Waverley Mills blankets, FY2025). Nullarbor-25 (25% MC; 425kg, fourth spin, Feb 2026). Nullarbor-30 (30% MC; 155kg, fourth spin, Feb 2026). The long-term aspiration since 2022 has been a staged scale-up toward 100% tree-free fibre
Key specifications/claimsA joint Birla/Nanollose patent application (Jan 2021) claimed a lyocell fibre finer than silk and significantly stronger than conventional wood-pulp lyocell (company statement). The fourth spin validated MC entering Birla's process with no extra pre-processing by Birla
Production partnersMC from HGB (Haikou, China); spinning by Birla Cellulose (India); yarns and fabrics by Paradise Textiles (India) and Waverley Mills (Australia)
Target customersMMCF producers (licensees); premium fashion and textile brands (demand pull)
Launch/latest versionFirst fibre 2017 (viscose route); lyocell pilot 2022; latest grades Feb 2026
Pricing modelNot publicly disclosed; target model is licensing/royalty
Flagship showcasesLee Mathews-designed garment (Première Vision Paris 2022; NGV 2025); merino/Nullarbor blankets (Waverley Mills, 2025); "Circular in the Square" (Perth). A high-profile international brand requested a 50kg specialised fibre grade in the June 2026 quarter, which management cautions may not be delivered in the short term

Nanollose microbial-cellulose pulp (enabling intermediate; future licensable product)

AttributeDetail
DescriptionPurified, dewatered MC pulp suited to lyocell dissolution. This is the output of the planned Western Australian Pilot Facility
Process statusLaboratory process at least 80% more efficient than the fourth-spin method, with one stage removed and better uniformity (22 Apr 2026). Dewatering pathway validated with a local consultant; washing validated with a European equipment supplier; initial equipment trials in the UK; dissolution validation in India in progress
Target capacityEnough pulp to support "multiple tonnes" of Nullarbor fibre per month (FY2026 Annual Report). Capex not yet determined
Pricing—

Nufolium™ (nonwoven fibre)

AttributeDetail
DescriptionTree-free rayon/lyocell-type fibre for nonwoven applications, chiefly wet wipes
Key milestone110kg of Nufolium-20 supplied to Glatfelter (now Magnera Corp., NYSE: MAGN), converted to nonwoven rolls (reported 2 Jul 2025) and shipped to Codi Group (European wipes maker supplying more than 40 countries) for sample wipes. Initial feedback was described as encouraging (FY2025 Annual Report)
Target customerHygiene and personal-care wipe manufacturers
StatusDeprioritised after the FY2026 strategic review

Biollose™ MicroGel / Jelli Grow (horticultural media)

AttributeDetail
DescriptionMC-based hydrogel seed-germination and growing medium; an alternative to soilless substrates such as rockwool or coir for vertical farming and microgreens
Key milestonesJelli Grow second patent grant (c. 2022). FY2025 trials with Greenspace (microgreens). Formulation refinements at HGB. Biollose national-phase patent filings in 12 jurisdictions (Jan 2026)
RevenueSmall historic sales (part of A$38.1k FY2023 and A$12.5k FY2024 sales revenue; split not disclosed)
StatusIP maintained; not a near-term focus

Leather-like nonwoven material

AttributeDetail
DescriptionAnimal-free, plastic-free biobased nonwoven positioned against bovine leather and petroleum-based "vegan leather"
Key milestoneCollaboration with South Metropolitan TAFE produced a haute-couture garment shown at Fremantle Design Week (FY2025)
StatusIP maintained; not a near-term focus

Financial Narrative

Basis: audited statutory accounts (AASB/IFRS), FY2022–FY2026, A$. Third-party aggregators (TipRanks) present Nanollose data on a mislabelled calendar-year basis; those figures are not used here.

Income statement

Table 6.1: Income statement (A$ thousand)

Sources: FY2026 Annual Report (five-year summary; P&L); FY2025 Annual Report (P&L). The FY2021 comparatives were a net loss of A$931.0k, EBITDA of A$-875.9k and EPS of -0.77c (FY2025 Annual Report).

Note on share-based payments: the FY2024 figure is a reversal (credit). The FY2026 figure is mainly CEO options (A$518k) and performance rights (A$55k).

Margins and growth. Gross, operating, EBITDA and net margins are not meaningful while sales revenue is nil or immaterial. The five-year revenue CAGR is not meaningful (base of zero).

Operating expense detail

Table 6.2: FY2025 vs FY2026 expense breakdown (A$ thousand; FY2026 Annual Report, with restated FY2025 comparatives)

Commentary. Losses have been remarkably stable in absolute terms (A$1.1–1.6m a year from FY2021 to FY2025), which reflects a deliberately lean cost base. FY2026 is an inflection: the reported loss rose 68% to A$2.39m. Most of the increase (A$632k) is non-cash share-based payments tied to the new CEO's package. Excluding share-based payments, the loss rose about A$336k (24%). Management attributes this to process-development work after the fourth spin, onshoring of analytics, and new engineering and operations capability. The corporate employee-benefits line rose 84% because FY2026 carried a full-time CEO (A$258k cash salary) alongside the Executive Chairman (A$242k). From 1 May 2026 the chairman's salary was cut to A$112,500 and a non-executive director's fee from A$60k to A$35k (effective 1 March 2026). That partially offsets the step-up from FY2027.

Balance sheet

Table 6.3: Balance sheet (A$ thousand, at 30 June)

Sources: FY2025 and FY2026 Annual Reports (statements of financial position and changes in equity). FY2023 cash is the FY2024 opening balance. Net debt is negative, meaning a net cash position.

Commentary. The balance sheet is almost entirely cash. Internally generated IP (15 granted patents, 8 trademarks) is expensed and carries no book value, so the A$1.2m equity understates any economic value of the IP. At 30 June 2024 the company had a deficiency in equity of A$224k; the FY2025 recapitalisation and the FY2026 option conversions restored positive equity. A A$200k short-term borrowing drawn in the December 2025 quarter (believed to be an R&D-incentive-style advance; terms not disclosed) was repaid in full. No lease liabilities remain because the Nedlands lease expired on 25 November 2025.

Cash flow

Table 6.4: Cash flow (A$ thousand)

Sources: FY2025 and FY2026 Annual Reports (statements of cash flows).

Commentary. FY2026 operating outflow of A$1.80m included about A$350k of FY2025 liabilities settled in July 2025, so the underlying cash burn was about A$1.45m. Capex has been nil for three years. That will change materially once Pilot Facility procurement begins in FY2027. Funding has come wholly from equity (placements, rights issues, option exercises) and the R&D Tax Incentive.

Ratios

Table 6.5: Key ratios

ROE in FY2024–FY2025 is not meaningful because of negative or near-zero average equity. ROA and ROE use average balances. The following ratios are not meaningful for a pre-revenue company with no EBITDA, interest-bearing debt or trading working capital: ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle.

Trend synthesis. The financial trajectory is one of survival funding, not operating improvement:

  • Cumulative accumulated losses reached A$14.6m by June 2026 against A$11.3m of issued capital.

  • The share count rose 2.4× between FY2024 and FY2026 (172m to 409m).

  • The key inflection is prospective. FY2027 will be the first year with meaningful capital expenditure (Pilot Facility), and management has explicitly said the full programme will require capital beyond existing cash.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Segment sales revenue (AUD K)

12.500

Segment total income incl. R&D incentive and interest (AUD K)

308.5243.5314.6

Segment EBITDA (AUD K)

-1,103.2-1,358.0-2,371.6

Segment EBIT (AUD K)

-1,139.1-1,393.8-2,386.2

Segment pre-tax result (AUD K)

-1,156.6-1,426.5-2,394.0

Contribution to total revenue (%)

100100100

Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

YoY change in pre-tax loss (%)

-14.123.367.8

Capital Programmes

ProgrammeStatus after FY2026 strategic review

Nullarbor™ (textile lyocell/rayon fibre)

Sole flagship; all capital directed here

Nufolium™ (nonwoven fibre for wipes)

Reported milestone July 2025; not a near-term focus

Biollose™ / MicroGel / Jelli Grow (horticulture)

IP maintained; not a near-term focus

Leather-like nonwoven material

IP maintained; not a near-term focus

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Sales revenue (AUD K)

038.112.500

R&D tax incentive income (AUD K)

——280.3231.6311.1

Total income incl. interest and other (AUD K)

——308.5243.5314.6

EBITDA (AUD K)

-1,505.1-1,324.8-1,103.2-1,358.0-2,371.6

EBIT (AUD K)

-1,570.1-1,361.6-1,139.1-1,393.8-2,386.2

Pre-tax income (AUD K)

-1,566.5-1,345.7-1,156.6-1,426.5-2,394.0

Net income (AUD K)

-1,566.5-1,345.7-1,156.6-1,426.5-2,394.0

Share-based payments expense (AUD K)

——-21.740.0672.0

Net loss excl. share-based payments (AUD K)

——-1,178.3-1,386.5-1,722.0

EPS basic (A$ cents)

-1.05-0.90-0.72-0.69-0.72

EPS diluted (A$ cents)

-1.05-0.90-0.72-0.69-0.72

Dividends per share (A$ cents)

00000

Expense line

Expense lineFY2025FY2026YoY change (%)

Research expenses (incl. R&D staff)

695.8817.817.5

– of which R&D employee costs

409.3418.82.3

– of which consultants and other R&D

286.5399.039.3

Employee benefits (corporate)

300.0552.684.2

Promotion and communication

148.8157.65.9

Consultancy and legal

138.8127.6-8.0

Depreciation and amortisation

35.814.6-59.3

Share-based payments

40.0672.01,580.1

Other expenses

275.6355.028.8

Interest expense

35.011.4-67.4

Balance Sheet and Share Count (m)

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD K)

—548.2138.8617.31,332.1

Total current assets (AUD K)

——185.9727.61,418.0

Total assets (AUD K)

——242.0747.81,423.7

Short-term debt incl. leases (AUD K)

——42.513.17.2

Long-term debt (AUD K)

——000

Total debt (AUD K)

——42.513.17.2

Net debt / (net cash) (AUD K)

——-96.3-604.2-1,324.9

Total liabilities (AUD K)

——465.6351.4225.4

Total equity (AUD K)

—451.6-223.7396.41,198.3

Goodwill and intangibles (AUD K)

00000

Working capital (AUD K)

——-279.8376.21,192.6

Accumulated losses (AUD K)

—-9,647.3-10,803.8-12,230.3-14,624.3

Shares on issue (m)

—148.9172.0305.1409.0

Cash Flow

MetricFY2024FY2025FY2026

Operating cash flow (AUD K)

-901.0-1,098.5-1,795.9

– incl. R&D incentive received (AUD K)

280.3231.6311.1

Capex (AUD K)

000

Free cash flow (AUD K)

-901.0-1,098.5-1,795.9

Investing cash flow (AUD K)

16.000

Equity raised, net of costs (AUD K)

503.01,606.62,523.8

Lease repayments (AUD K)

-27.5-29.4-13.1

Financing cash flow (AUD K)

475.51,577.12,510.8

Dividends paid (AUD K)

000

Buybacks (AUD K)

000

Net change in cash (AUD K)

-409.5478.6714.8

Financial Ratios (x) and Returns & Leverage Ratios (%)

RatioFY2024FY2025FY2026

Current ratio (x)

0.402.076.29

Debt to equity (x)

n/m

0.030.01

ROA (%)

—-288.2-220.5

ROE (%)

n/m

n/m

-300.3

Cash burn cover (cash ÷ annual operating outflow, years)

0.150.560.74

Revenue by Region

RegionFY2024FY2025FY2026

Australia (AUD K)

12.500

Rest of world (AUD K)

000

Country Overview

CountryActivityStatus

China (Haikou, Hainan)

MC fermentation and supply (HGB)

Ongoing long-term supply partner

India

Lyocell dissolution and spinning (Birla Cellulose); yarn and fabric (Paradise Textiles)

Ongoing

United Kingdom

Initial washing/dewatering equipment trials

Completed FY2026

Europe (country not disclosed)

Washing-at-scale equipment trial

Completed FY2026

Europe (Codi Group); USA (Magnera)

Nonwovens/wipes trials

Deprioritised

Australia (Western Australia)

Head office, onshored analytics, planned Pilot Facility

Expanding

Share Price and Share Count (m)

MetricFY2021FY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.0900.0710.0550.0250.0670.050

Shares on issue at 30 June (m)

——148.9172.0305.1409.0

Implied market cap at 30 June (AUD Mn)

——8.24.320.420.4

Share Price History

PeriodPrice moveReturn

1-year

A$0.067 → A$0.050

-25.4%

3-year

A$0.055 → A$0.050

-9.1%

5-year

A$0.090 → A$0.050

-44.4%

Since IPO (A$0.20, Oct 2017)

A$0.20 → A$0.050

about -75%

Valuation Multiples

MultipleNanolloseSpinnovaLenzing

Market cap

~A$20.4m

——

Enterprise value

~A$19.1m (market cap minus A$1.33m cash plus A$0.01m debt)

——

P/E

n/m (loss)

n/m (loss)

n/m (FY2025 net loss)

EV/EBITDA

n/m

n/m

—

EV/Sales

n/m (nil revenue). Multiples.vc showed about 2,450× on a trailing A$9k revenue figure, which is not meaningful

n/m

—

P/B

~17.0× (A$20.4m ÷ A$1.20m)

——

Fully diluted shares

~488.5m (409.0m + 73.5m options + 6.0m rights)

——

Class Details

ClassNumberExercise priceExpiryPotential proceeds (AUD K)

NC6OB (listed)

29,405,0000.05

6 Feb 2027

1,470

NC6OPT11

9,638,892

0.025 / 0.035 / 0.045 (tiered by year)

30 Apr 2028

~337 (at 0.035)

NC6OPT12 (CEO)

15,000,0000.07

14 Jul 2028

1,050

NC6OPT13 (CEO)

15,000,0000.10

14 Jul 2028

1,500

NC6OPT14

2,500,0000.05

6 Feb 2027

125

NC6OPT16

1,000,0000.066

3 Dec 2028

66

NC6OPT17

1,000,0000.10

31 Jan 2029

100

Total

73,543,892——

~4648

Analyst Conclusions

Management guidance

No quantitative guidance has been given. The FY2027 operating objectives are:

  1. Secure and fit out Western Australian premises.

  2. Complete the equipment tender and disclose the Pilot Facility's cost, configuration and output.

  3. Commission onshore analytical and processing equipment.

  4. Complete larger-volume dewatering and washing trials.

  5. Build, commission and run the Pilot Facility.

  6. Advance dissolution validation in India.

  7. Convert partner evaluations into formal commercial arrangements.

  8. Pursue non-dilutive grant funding.

The FY2026 Annual Report outlook calls this a "year focused on delivery."

Consensus

None available (no coverage).

Bull case

  1. Cheap option on a large market. An enterprise value of about A$19m buys a validated drop-in feedstock for an 8.4mt, US$20bn industry. Even a single royalty-bearing licence with a major such as Birla Cellulose, covering a small fraction of lyocell output, could justify a multiple of today's value. Licensing needs no Nanollose-funded industrial capex.

  2. Technical de-risking is visible. The fourth spin removed partner pre-processing and the April 2026 lab process cut a stage while lifting efficiency by at least 80%. Equipment vendors have expressed confidence in scalability. The questions have shifted, as management says, "from invention to engineering," and the newly hired Tesla- and Sandvik-experienced engineers suit that phase.

  3. Regulatory pull. EUDR compliance and brand deforestation pledges create urgency for non-forest feedstocks, while incumbents' existing assets make a drop-in solution the path of least resistance. The unsolicited 50kg brand request signals real demand.

Bear case

  1. Funding arithmetic. Cash of A$1.33m against a burn of about A$1.5–1.8m a year before capex, plus an undisclosed Pilot Facility cost that management admits exceeds existing reserves. Raising at about A$0.05 means significant dilution on top of the 2.4× share-count increase since FY2024, and going-concern uncertainty persists.

  2. Execution and track record. Four pilot spins and about nine years since IPO have produced no binding offtake or licence. The strategy changed twice within FY2026, and laboratory-scale gains have historically failed to translate at pilot scale across the biomaterials sector. The economics of bacterial-cellulose fermentation at commodity cost remain unproven, and management concedes it lacks the operating data.

  3. Governance and counterparty concentration. A three-person board without a clearly independent director, related-party service providers, and dependence on one Chinese supplier and one Indian spinner (who co-owns key IP) weaken negotiating leverage and oversight just as the company enters a capital-intensive phase.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhy it matters
By 31 Oct 2026September-2026 quarterly / 4CCash burn, equipment arrival, site status
By 12 Nov 2026AGMBoard renewal (independent director appointment?), placement capacity resolutions (ASX Listing Rule 7.1A)
H2 CY2026Pilot Facility cost and configuration disclosureSizes the funding requirement; key valuation input
H2 CY2026Western Australian premises securedExecution milestone
H2 CY2026 – H1 CY2027Larger-volume dewatering and washing trials; dissolution validation in IndiaTechnical de-risking
H2 CY2026Paradise Textiles yarn and fabric output from the fourth spin; brand feedbackDemand validation
H2 CY202650kg specialised-grade delivery to the international brandBrand relationship signal
Mar-2027 quarterFY2026 R&D Tax Incentive refundNon-dilutive cash (about A$0.3–0.4m expected)
6 Feb 2027NC6OB option expiry ($0.05)Up to A$1.47m if in-the-money; at-the-money today
CY2027Capital raise, grant award, or partner-funding announcementDetermines dilution and timeline
OngoingAny binding licence, JV, offtake or strategic transactionThe single largest value catalyst

Concluding analyst verdict

Nanollose is a binary, pre-revenue technology option. Its investment case has improved materially in quality over the past 18 months, but its financial capacity to deliver remains thin.

On the positive side, the company now has a clearer strategy than at any point since its 2017 IPO. It has narrowed to a single flagship pathway (Nullarbor), a capital-efficient end-state (licensing into existing lyocell plants), and a concrete near-term objective (a self-controlled Western Australian Pilot Facility). The fourth Birla Cellulose pilot spin in February 2026 provided the most convincing evidence yet that microbial cellulose can act as a drop-in, incremental feedstock. The subsequent laboratory process improvement, if it holds at pilot scale, addresses the historic Achilles' heel of bacterial cellulose: processing cost and consistency. Management's tone is notably candid, setting measurable markers and openly listing what has not been achieved. Structural tailwinds from the EU Deforestation Regulation and brand traceability commitments are genuine.

Against this, the balance sheet cannot carry the plan. With A$1.33m of cash at 30 June 2026, an underlying burn of about A$1.5m a year and a facility of undisclosed cost, Nanollose will almost certainly need to raise material new capital within the next two to three quarters. At the current share price that implies further heavy dilution, unless non-dilutive grants or a partner co-investment materialise. Governance is below best practice for a company entering a capital-intensive phase. The absence of any binding commercial agreement, four years after the first pilot spin, keeps commercial risk high.

Verdict. Treat this as speculative. The probability-weighted value hinges on three disclosures in the next 6–12 months: the Pilot Facility cost, the funding structure, and evidence of a licence-grade counterparty commitment (most plausibly Birla).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleAppointed / tenurePrior rolesEducation

Dr Wayne Best

Executive Chairman

Executive service agreement from 10 Apr 2018; full-time at Nanollose since 2018

About 40 years in organic chemistry. Founder and MD of Epichem Pty Ltd (contract research/drug discovery, 14 years). Chemistry Centre (WA), where he formed the Medicinal & Biological Chemistry Section (10 years). ICI Australia Research Group (4.5 years). Adjunct Associate Professor at Murdoch University and UWA

BSc (Hons), PhD Organic Chemistry (UWA); DIC (Imperial College); FRACI; GAICD

Andrew Moullin

Managing Director & CEO

Since 14 Jul 2025

Commercial Projects & Senior Corporate Lawyer, Iluka Resources. Roles at DLA Piper, Macro Metals, Fivemark Partners, CLSA. Founded several businesses with exits

LLB; BA (Psychology); Grad Dip Applied Finance; GAICD; FGIA

Winton Willesee

Non-Executive Director; Joint Company Secretary

Since 18 Oct 2017

More than 20 years in Australian capital markets. Current NED of One Click Group (ASX:1CG) and KTEK Aerosystems (ASX:KTK, from 20 Mar 2026). Former NED of Neurotech International and Bridge SaaS

BBus, DipEd, PGDipBus, MCom; FFin; CPA; GAICD; FGIS/FCIS

Heidi Beatty

Non-Executive Director (resigned)

8 Jul 2019 – 1 Apr 2026

Founder of Crown Abbey Ltd (consultancy); 10 years at Johnson & Johnson (Europe/US)

BSc Chemistry (University of York)

Timothy Barker

Joint Company Secretary

Since Apr 2025

Not detailed

LLB (English and French Law); MSc International Business Management

Danielle Nardini

Operations & Engineering Manager (not KMP)

Appointed Jun 2026; started Jul 2026

More than 16 years in engineering and operations. Sandvik (scale-up of battery-electric mining systems); Sustainability Principal at Sandfire Resources

Master's and BSc in Industrial Engineering

Peter Hillier

Process engineering consultant

Engaged Aug 2026

Founder and lead process engineer; more than 15 years of scale-up experience

—

Dr Jacob Brown

Chemical engineering consultant

Engaged Aug 2026

Former senior chemical engineer at Tesla (electrode active materials); founder of a metal-extraction start-up

PhD Chemical Engineering (Cambridge)

Scott Williams

Corporate Advisor (Fiftyone Capital)

12-month mandate from Aug 2025

Founder and principal of Fiftyone Capital (est. 2018)

—

“—” = not publicly disclosed.

Directors' Remuneration

NameCash salary/feesSuperannuationLeaveOptions (SBP)Performance rights (SBP)TotalFixed %At-risk %

Wayne Best

241,66729,00010900270,7761000

Andrew Moullin

257,66930,92011,641518,16554,942873,3373466

Winton Willesee

51,667000051,6671000

Heidi Beatty

45,0000025,179070,1796436

Total

596,00359,92011,750543,34454,9421,265,959——

Directors' Remuneration (Annual)

MetricFY2024FY2025FY2026

Total KMP remuneration (AUD K)

316.3374.21,266.0

Executive Leadership Team by Person

PersonChange

Wayne Best

A$225k → A$267.5k from 1 Jul 2025, then cut to A$112.5k from 1 May 2026

Andrew Moullin

A$267k plus superannuation

Winton Willesee

A$60k → A$35k from 1 Mar 2026

Governance Detail

Related entityLinked director(s)ServiceAmount paid

Epichemistry Pty Ltd

Best and Willesee

Chemical research and analysis

A$17,100

Azalea Corporate Services

Willesee

Corporate, accounting and company secretarial services

A$135,600

Major Shareholders

HolderShares% at noticeNotice date

WACC Pty Ltd ATF Flagship Fund

25,019,9708.21

21 May 2025

Azalea Family Holdings Pty Ltd (Willesee family trust)

24,858,006 (24,258,006 at Aug 2026)

8.15

26 May 2025

Wayne Morris Best

22,400,0007.35

26 May 2025

ConBrio Beteiligungen AG

20,625,0006.77

20 May 2025

Fiftyone Capital Pty Ltd

Described as an existing substantial shareholder; it exercised 30m options in FY2026. Exact current holding not publicly disclosed in sources reviewed

——

Dutch Ink (2010) Pty Ltd

Held 33.4m NC6OPT11 options at Aug 2025. Since 1 April 2026 these options have largely been converted (NC6OPT11 options outstanding fell from 111.7m to 9.6m), so a material shareholding is likely but unconfirmed

——

Competitive Landscape

Key Competitors

CompetitorCountry / listingTechnology / positionLatest reported scaleRelative positioning vs Nanollose

Lenzing AG

Austria / Vienna (LNZ)

Incumbent lyocell, modal and viscose (TENCEL™, ECOVERO™, VEOCEL™) from wood pulp; integrated dissolving pulp in Brazil

FY2025 revenue about €2.6bn (down 2.3%); adjusted EBITDA €425.6m; net loss €135.2m; about 17,700 FTE; 61% of revenue from Asia

Potential licensee or customer as much as competitor; huge scale advantage; wood-pulp based

Birla Cellulose (Grasim Industries)

India / NSE-BSE (via Grasim)

Major global MMCF producer (viscose, lyocell); Nanollose's spinning partner

—

Partner and most likely licensee; could develop alternatives internally

Sateri (RGE Group)

China / private

Large viscose and lyocell producer; recycled-feedstock initiatives

—

Incumbent; potential licensee

Tangshan Sanyou

China / Shanghai

Large viscose producer

—

Incumbent

Kelheim Fibres

Germany / private

Specialty viscose for hygiene and nonwovens

—

Relevant to the (now deprioritised) Nufolium market

Spinnova Plc

Finland / Nasdaq Helsinki (SPINN)

Mechanical wood/waste-to-fibre with no dissolving chemicals

FY2025 revenue €344k (2024: €762k); net loss €40.7m; cash and investments €44.4m; 68 granted patents. Sources differ on operating loss: €41.3m (FashionUnited) vs €23.8m (Quartr summary). The gap likely reflects impairment classification

Closest listed next-gen fibre peer; better funded but also pre-commercial and restructuring

Circulose (formerly Renewcell)

Sweden / private

Textile-to-textile recycled dissolving pulp; drop-in for viscose and lyocell

—

Direct competitor for "alternative feedstock" slots in MMCF lines

Infinited Fiber Company

Finland / private

Textile-waste regenerated fibre (carbamate process)

—

Competes for brand partnerships; requires new process plant

Evrnu

USA / private

Recycled-cotton regenerated fibre (NuCycl)

—

Brand-facing competitor

Polybion

Mexico / private

Bacterial-cellulose biomaterials (leather alternatives)

—

Direct technology analogue in the deprioritised leather segment

Modern Meadow / Bolt Threads and other biomaterials players

USA / private

Biofabricated materials

—

Compete for brand sustainability budgets

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricNanollose FY2026 (AUD)Spinnova FY2025 (EUR)Lenzing FY2025 (EUR)

Revenue

00.344

~2,600

Revenue growth (%)

n/m

-54.9-2.3

EBITDA margin (%)

n/m

n/m

16.4 (adjusted)

Net result

-2.39-40.7-135.2

Cash

1.33

44.4 (incl. current investments)

Liquidity ~910+

R&D intensity

n/m (pre-revenue)

n/m

—

Company Snapshot

971,000

Employees

2014

Founded

Nedlands, Australia

Headquarters

SWOT Analysis

Strengths

  • Industrial validation. Four pilot spins with Birla Cellulose on commercial lyocell equipment. The latest (Feb 2026) produced 580kg, the largest to date (FY2026 Annual Report).
  • Drop-in feedstock. The fourth spin was the first in which MC entered Birla's process with no extra pre-processing, which lowers adoption barriers (FY2026 Annual Report).
  • Process improvement. At least 80% efficiency gain and one production stage eliminated at laboratory scale (ASX, 22 Apr 2026).
  • IP portfolio. 15 granted patents and 8 trademarks across four families, with new grants in Japan, Canada and South Korea in Jan 2026 (FY2026 Annual Report).
  • Improved liquidity and a clean balance sheet. Cash more than doubled to A$1.33m, total liabilities are only A$225k, and debt is effectively nil (FY2026 balance sheet).
  • Downstream proof points. Finished blankets (Waverley Mills), designer garments (Lee Mathews), and nonwoven wipes (Magnera/Codi) show textile-chain compatibility (FY2025–FY2026 Annual Reports).
  • Strengthened scale-up team. Operations and engineering hire, plus Cambridge and Tesla-experienced process engineers (21 Aug 2026).

Weaknesses

  • No operating revenue. Nil in FY2025 and FY2026; best-ever sales were A$38.1k (FY2023) (five-year summary).
  • Persistent losses and going-concern uncertainty. Accumulated losses of A$14.6m; the auditor flags a material uncertainty in both FY2025 and FY2026.
  • Short cash runway. FY2026 operating burn of A$1.80m against A$1.33m of cash, before any Pilot Facility capex.
  • Board governance gaps. Three-person board with no clearly independent director; executive chair; related-party service providers (A$152.7k paid in FY2026).
  • High dilution history. Shares rose from 148.9m (FY2023) to 409.0m (Aug 2026), and a further 73.5m options plus 6m rights remain outstanding.
  • Slow commercialisation. The first pilot spin was in 2022, yet the company still has no binding supply, licensing or offtake agreement (stated in the FY2026 Annual Report).
  • Third-party dependence. Arrangements with HGB, Birla and Paradise are not exclusive, and some are not long-form binding agreements (FY2026 risk section).

Opportunities

  • Large addressable market. 8.4mt of MMCF output and a US$20bn regenerated cellulosic market; even small feedstock penetration via licence would be material relative to a roughly A$20m market capitalisation.
  • Regulatory tailwind. EUDR and traceability requirements raise demand for non-forest feedstock (cited in the FY2026 chairman's letter).
  • Brand pull. A high-profile international brand requested a 50kg specialised grade (June 2026 quarter).
  • Non-dilutive funding. Onshore Australian R&D activity may qualify for grants (advisor engaged) in addition to the R&D Tax Incentive (A$311k in FY2026).
  • Option-funded capital. 29.4m NC6OB options at $0.05 could bring in about A$1.47m by Feb 2027, and 9.6m NC6OPT11 options could bring in about A$0.34m at the current $0.035 tier.
  • Optionality in shelved assets. Biollose (12-jurisdiction filings), the leather-like material and Nufolium could be out-licensed or sold to fund the core programme.

Threats

  • Scale-up failure. Laboratory results may not replicate at pilot scale (the company's own risk statement); no supplier has yet been committed.
  • Capex funding gap. The Pilot Facility cost is undisclosed, and management expects it to require capital beyond existing cash. Raising capital at about A$0.05 a share implies heavy dilution.
  • Better-capitalised rivals. Spinnova (about €44m of cash), Circulose and Infinited compete for the same brand and producer attention.
  • Incumbent cycle weakness. Lenzing's FY2025 net loss of €135m and revenue decline signal limited capex appetite among potential licensees.
  • Geopolitical and supply-chain risk. MC supply from China and spinning in India are exposed to tariffs and export controls (FY2026 risk section).
  • Partner bargaining power. Birla holds joint IP and controls pilot spinning, which may weaken Nanollose's negotiating leverage in any licence.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Waverley Mills produces about 70 merino/Nullarbor-20 blanketsFirst finished consumer product; validates mill compatibility
11 Apr 2025Joint company secretaries appointedGovernance administration
30 Apr 2025Quarterly update highlights Nullarbor and Biollose progressRoutine
May 2025Rights-issue shortfall placed (A$1.05m); 85.7m Dutch Ink strategic options issued (20 May)Balance-sheet repair; new strategic holder
20–26 May 2025Substantial-holder notices from WACC Flagship Fund, Azalea (Willesee), Best and ConBrioRegister consolidation
29–30 May 2025CEO-designate options (30m) and performance rights (6m) issuedIncentive alignment
11 Jun 20252.5m options issued to a consultant in lieu of feesCash preservation
2 Jul 2025Magnera converts 110kg of Nufolium-20 into nonwoven rolls, shipped to CodiNonwoven validation
14 Jul 2025Andrew Moullin starts as CEO and Managing DirectorLeadership transition
1 Aug 2025Fiftyone Capital A$750k commitment; Scott Williams appointed Corporate AdvisorFunding certainty
28 Aug 2025NGV "Making Good" exhibition opens with Nullarbor itemsBrand visibility
29 Aug 2025FY2025 Annual Report: loss of A$1.43m; going-concern uncertaintyResults
Sep-2025 quarterFirst A$250k Fiftyone tranche receivedFunding
7 Nov 2025AGM: remuneration report passed with 91.43% support; options to Beatty approvedGovernance
Dec-2025 quarterA$200k short-term borrowing drawnLiquidity bridge
FY2026 H1Strategic review narrows the portfolio to NullarborStrategic pivot
22 Jan 2026Patent grants in Japan, Canada and South Korea; Biollose filings in 12 jurisdictionsIP strengthening
Mar-2026 quarterR&D Tax Incentive refund of A$311k received; borrowing repaidNon-dilutive funding
Feb 2026Fourth pilot spin completed: 580kg Nullarbor-25 and -30Largest run; feedstock "drop-in" validated
27 Feb 2026Half-year report: loss of A$1.53m (up 110%); nil revenue; negative net tangible assets of A$-170k at 31 Dec 2025Results; balance-sheet stress before option conversions
1 Mar 2026Non-executive director fee cut to A$35kCost control
16 Mar 2026Heidi Beatty resigns (effective 1 Apr 2026)Board shrinks to three
Mar-2026 quarterCapital-light, partner-backed two-stage build describedLater superseded
8 Apr 2026CEO Letter to Shareholders sets out rationale and measurable objectivesStrategy communication
22 Apr 2026At least 80% lab efficiency gain; stage removed; global equipment tenderTechnical inflection
1 May 2026Executive Chairman's salary cut to A$112.5kCost control
6 May 2026A$1.58m raised through option conversionsFunding
Jun-2026 quarterOnshoring of analytics begins; Danielle Nardini appointedCapability build
Jun-2026 quarterHigh-profile international brand requests a 50kg specialised fibre sampleDemand signal (non-binding)
31 Jul 2026June-quarter Appendix 4C: cash of about A$1.35mRoutine
21 Aug 2026Single Pilot Facility pathway confirmed; Hillier and Brown engaged; dewatering pathway validatedStrategy refinement
31 Aug 2026FY2026 Annual Report: loss of A$2.39m (up 68%); cash of A$1.33m; going-concern material uncertaintyResults
24 Sep 2026Closing date for AGM director nominationsGovernance
By 31 Oct 2026 (due)September-2026 quarterly activities report and Appendix 4C–
By 12 Nov 2026 (expected)FY2026 AGMUpcoming catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Sales revenue held from AUD 0 Mn in FY2022 to AUD 0 Mn in FY2026.
Nanollose Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Sales revenue00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Nanollose Limited, Appendix 4E and Annual Report for the year ended 30 June 2026 (ASX, 31 Aug 2026) (bulletin.webull.com)
  2. Nanollose Limited, Appendix 4E and Annual Report for the year ended 30 June 2025 (ASX, 29 Aug 2025) (announcements.asx.com.au)
  3. Nanollose Limited, Half-Year Report to 31 December 2025 (ASX, 27 Feb 2026) (announcements.asx.com.au)
  4. InvestSMART summaries of NC6 price-sensitive announcements (FY2025 Annual Report; HY2026 report)
  5. Nanollose Annual Report FY2020 (ASX, 25 Aug 2020) (asx.com.au)
  6. Nanollose Annual Report FY2021 ( (weblink.com.au)
  7. Nanollose December 2017 quarterly update (BioSpace / ABN Newswire)
  8. Birla Cellulose press release on the first pilot spin (March 2022), via renewable-carbon.eu, knittingindustry.com and innovationintextiles.com
  9. Kalkine Media: "Nanollose Secures $1.58M via Option Conversions…" (31 Jul 2026)
  10. Ragtrader: "Aussie bio-textile firm Nanollose onshores production" (2026)
  11. Stockwirex: "Nanollose Ltd Refines Pathway to Single Pilot Facility" (Aug 2026)
  12. TipRanks: NC6 company announcements, income statement and revenue pages
  13. Stockopedia, multiples.vc, financialfilings.com, Kalkine, Morningstar, roic.ai, Musaffa (aggregator data; used for market cap, ISIN and profile cross-checks only)
  14. StartupSmart / SmartCompany (2017 IPO article); just-style (2017 IPO article); Stockhead (2021 joint patent; 2022 quarterly); SmallCaps; Proactive Investors (PT SNU facility)
  15. Lenzing FY2025 results via knittingindustry.com, finder.techleap.nl and the Lenzing FY2025 investor presentation
  16. Spinnova FY2025 results via FashionUnited, Inderes (Financial Statements Bulletin 2025) and Quartr

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.